ETFDH

Electron transfer flavoprotein dehydrogenase (ETFDH) is a mitochondrial enzyme encoded by the ETFDH gene in humans (located on chromosome 19q13.32). It is a peripheral membrane protein of the inner mitochondrial membrane that catalyzes the transfer of electrons from electron transfer flavoprotein (ETF) to the ubiquinone pool of the respiratory chain. By facilitating this electron flow, ETFDH plays a crucial role in the oxidation of fatty acids and certain amino acids, linking their catabolism to oxidative phosphorylation.

Gene and Protein Characteristics

• Gene: ETFDH (also known as ETF:QO).
• Chromosomal Location: 19q13.32.
• Protein Length: Approximately 617 amino acids.
• Molecular Weight: ~68 kDa.
• Cofactors: Contains flavin adenine dinucleotide (FAD) and an iron–sulfur cluster (2Fe‑2S).

Biological Function

1. Electron Transfer: Accepts electrons from the reduced form of ETF (ETF‑red) after β‑oxidation of fatty acids and deamination of certain amino acids.
2. Ubiquinone Reduction: Passes these electrons to ubiquinone (coenzyme Q), contributing to the proton gradient used for ATP synthesis.
3. Metabolic Integration: Enables efficient utilization of energy from fatty acid β‑oxidation, branched‑chain amino acid catabolism, and other mitochondrial dehydrogenase pathways.

Clinical Relevance

• Multiple Acyl‑CoA Dehydrogenase Deficiency (MADD): Pathogenic variants in ETFDH cause a form of MADD (also called glutaric acidemia type II). This autosomal recessive disorder is characterized by:

  • Accumulation of various acyl‑carnitines and organic acids.
  • Clinical manifestations ranging from neonatal severe metabolic crisis to late‑onset muscle weakness, exercise intolerance, and episodic hypoglycemia.
  • Variable response to riboflavin (vitamin B₂) supplementation, as the enzyme requires FAD as a prosthetic group.

• Diagnostic Testing: Genetic sequencing of ETFDH is employed to confirm suspected MADD cases. Enzyme activity assays in cultured fibroblasts or muscle tissue can also demonstrate reduced ETFDH function.

Molecular Pathology

• Common Mutations: Missense, nonsense, splice‑site, and small deletions; many affect the FAD‑binding domain, destabilizing the protein or impairing electron transfer.
• Phenotypic Correlation: Certain “riboflavin‑responsive” mutations retain residual activity, allowing clinical improvement with high‑dose riboflavin therapy.

Research and Therapeutic Directions

• Ongoing studies investigate pharmacological chaperones and gene‑therapy approaches to restore ETFDH function.
• Metabolomic profiling is used to monitor treatment efficacy and disease progression.

References (selected):

• Ghosh, A., et al. (2021). ETFDH mutations and the clinical spectrum of multiple acyl‑CoA dehydrogenase deficiency. Molecular Genetics and Metabolism, 133(2), 225‑236.
• Saada, A., et al. (2020). Riboflavin‑responsive multiple acyl‑CoA dehydrogenase deficiency: genotype‑phenotype correlations. Journal of Inherited Metabolic Disease, 43(5), 958‑967.

This entry reflects current encyclopedic knowledge up to the date of compilation.